Eton Pharmaceuticals (ETON) Short term Debt (2021 - 2026)

Eton Pharmaceuticals has disclosed Short term Debt across 6 years of filings, most recently posting $8.8 million for Q2 2026.

• In Q2 2026, Short term Debt rose 218.71% year-over-year to $8.8 million; the TTM figure through Jun 2026 stood at $8.8 million (up 218.71% YoY), while the FY2025 annual figure was $8.8 million, changed N/A from the prior year.
• Short term Debt came in at $8.8 million for Q2 2026 at Eton Pharmaceuticals, roughly flat from $8.8 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $8.8 million in Q2 2026 to a low of $364000.0 in Q2 2022.
• Average Short term Debt over 5 years is $3.5 million, with a median of $2.8 million recorded in 2025.
• Year-over-year, Short term Debt slumped 51.4% in 2022 and surged 420.81% in 2023.
• Over 5 years, Short term Debt stood at $1.0 million in 2022, then surged by 420.81% to $5.4 million in 2023, then decreased by 23.33% to $4.1 million in 2024, then surged by 113.07% to $8.8 million in 2025, then climbed by 0.41% to $8.8 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $8.8 million in Q2 2026, $8.8 million in Q4 2025, and $2.8 million in Q3 2025.